Sort   by:  
 Page size 
MetabolomicsApoptosis-inducing effects of aqueous extract of Eleutherococcus senticosus on non-small cell lung cancer cell proliferation

Non-small cell lung cancer is a malignant tumor with high morbidity and mortality worldwide. Eleutherococcus senticosus can induce apoptosis in non-small cell lung cancer cells, but the mechanism remains unclear. This study aimed to elucidate the role of Eleutherococcus senticosus in inducing apo...

2025-05-12 | MTBLS10545 | MetaboLights
MetabolomicsA blood-based metabolic signature for earlier detection of lung cancer

Metabolomic profiling was applied to 1,259 sera collected within five years of a lung cancer diagnosis and 8,470 non-case sera from ever-smoker participants in the Prostate Lung Colorectal and Ovarian (PLCO) Study to identify metabolic signatures for the earlier detection of lung cancer. We devel...

2026-08-20 | MTBLS15406 | MetaboLights
MetabolomicsNon-invasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer
Lung cancer remains the most common cause of cancer deaths worldwide, yet there is currently a lack of diagnostic noninvasive biomarkers that could guide treatment decisions. Small molecules (<1500 Da) were measured in urine collected from 469 lung cancer patients and 536 population controls using u...
2014-05-06 | MTBLS28 | MetaboLights
MetabolomicsCirculating cell populations as response predictors and targets to improve immunotherapy in metastatic lung cancer

The effectiveness of immunotherapy varies among patients with advanced non-small cell lung cancer (NSCLC). Here we investigated the baseline immune status in stage IV NSCLC patients treated with anti-PD-1 plus chemotherapy to understand the immune mechanisms and unveil systemic markers associated...

2025-10-16 | MTBLS13150 | MetaboLights
MetabolomicsTemporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment
Lung cancer causes more deaths in men and women than any other cancer related disease. Currently, few effective strategies exist to predict how patients will respond to treatment. We evaluated the serum metabolomic profiles of 25 lung cancer patients undergoing chemotherapy ± radiation to evaluate t...
2017-01-19 | MTBLS200 | MetaboLights
MetabolomicsTargeting GSTZ1 sensitizes KRASG12C-mutant lung cancer cells by overcoming glutathione and glycolysis pathway rewiring

KRAS mutations are prevalent in lung cancer, but KRAS G12C inhibitors exhibit limited efficacy, partly due to metabolic adaptations, such as enhanced glutathione metabolism and increased glycolysis. Glutathione S-Transferase Zeta 1 (GSTZ1) is a metabolic enzyme that regulates cell metabolism. How...

2026-05-15 | MTBLS12791 | MetaboLights
MetabolomicsSearching for Drug Synergy Against Cancer Through Polyamine Metabolism Impairment: Insight Into the Metabolic Effect of Indomethacin on Lung Cancer Cells
Non-small cell lung cancer (NSCLC) is the most lethal and prevalent type of lung cancer. In almost all types of cancer, the levels of polyamines (putrescine, spermidine, and spermine) are increased, playing a pivotal role in tumor proliferation. Indomethacin, a non-steroidal anti-inflammatory drug, ...
2021-02-08 | MTBLS873 | MetaboLights
MetabolomicsGut Microbiota Dysbiosis and Hypercholesterolemia Are Associated with Bone Metastasis in Non-Small Cell Lung Cancer
We collected baseline fecal samples from 85 patients with newly diagnosed lung cancer, 51 patients with bone metastasis (M group), and 34 patients without bone metastasis (N group). We conducted metagenomic and metabolomic sequencing to compare the differences in gut microbiota and metabolites betwe...
2026-07-10 | MTBLS15004 | MetaboLights
MetabolomicsChanges in L-phenylalanine concentration reflect and predict response to anti-PD-1 treatment combined with chemotherapy in patients with non-small cell lung cancer
Chemotherapy combined with checkpoint blockade antibodies targeting programmed cell death protein (PD-1) has achieved remarkable success in non-small cell lung cancer (NSCLC). However, few patients benefit from long-term treatment. Therefore, biomarkers capable of guiding the optimal therapeutic sel...
2025-06-16 | MTBLS11232 | MetaboLights
MetabolomicsCorrelation between gut microbiota and their metabolites and the efficacy of chemotherapy combined with immunotherapy for extensive-stage small cell lung cancer

Gut microbiota has been reported to be associated with the host’s immune system and immunotherapy response, as well as immune-related adverse events (irAEs). Additionally, gut microbial metabolites have various immunomodulatory effects. Our study focused on the differences in gut microbiota and t...

2025-12-23 | MTBLS13557 | MetaboLights
Sort   by:  
 Page size